Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Novel Compounds May Help Protect Against Respiratory Depression
A paper that appears in the June 2009 issue of Anesthesiology details how AMPAKINE CX717, a Phase II compound created by Irvine, California-based neuroscience company Cortex Pharmaceuticals, demonstrated the rescue of fentanyl-induced respiratory depression and sleep apnea in rats. In this same study, CX717 demonstrated equal efficacy with the opioid antagonist Naloxone, a drug used to counter the effects of opioids on suppression of breathing. CX717 did not, however, interfere with the action of pain-killing opiates. This offers a distinct advantage compared with Naloxone and could provide a novel therapeutic means of treating those patients who are particularly prone to breathing depression with opiates while achieving maximum pain relief.
generic viagra online
Advaxis Receives FDA Response To Orphan Drug Filing
Advaxis, Inc. (OTCBB:ADXS) received the FDA letter late on June 1 denying the company"s request for Orphan Drug Designation (ODD) for the use of ADXS11-001 in invasive cervix cancer. The FDA stated their market definition for invasive cervical cancer prevalence (including all those who had been cured) is over the 200,000 person cutoff. Further, the applicability of ADXS11-01 for a precursor condition, cervical intraepithelial neoplasia (CIN) was considered by the ODD as an early manifestation of the disease. No prevalence estimate for CIN was provided in our original application. There was no issue raised about efficacy.
News of the day
Ignorance May Not Be Bliss, Brain Response To Information About The Future Suggests
New research demonstrates that single neurons in the reward center of the brain process not only primitive rewards but also more abstract, cognitive rewards related to the quest for information about the future. The study, published by Cell Press in the July 16 issue of the journal Neuron, enhances our understanding of learning and suggests that current theories of reward should be revised to include the effect of information seeking.
Sexual Health

KCI Announces FDA Clearance Of ABThera™ Open Abdomen Dressing

Kinetic Concepts, Inc. (NYSE: KCI) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its ABThera™ Open Abdomen Dressing. Earlier this year, the FDA cleared the ABThera™ Open Abdomen Negative Pressure Therapy Unit. Together, the ABThera™ Open Abdomen Negative Pressure Therapy System will be indicated for temporary bridging of abdominal wall openings where primary closure is not possible or repeat abdominal entries are necessary. The intended use of the system is for open abdominal wounds, with exposed viscera, including but not limited to abdominal compartment syndrome. This unique, proprietary system is designed to improve therapy in the management of the complex open abdomen by actively removing fluids and infectious material, and by reducing interstitial edema, thus assisting in primary fascial closure of abdominal wall. The ABThera™ Open Abdomen Negative Pressure Therapy System expands the offerings of KCI"s negative pressure technology platform into the surgical and trauma operating theaters. "We are pleased to receive clearance for this important therapy," said Catherine M. Burzik, KCI"s President and CEO. "At KCI, we continue to leverage our strengths and core technology competencies to provide high impact therapies and address clinical unmet needs. Expansion and growth in the surgical arena is a strategic goal for the company and we look forward to launching the ABThera™ Open Abdomen Negative Pressure Therapy System this summer." Kinetic Concepts, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009